| | Scenarios | Total cost ($) | Total effectiveness (QALY) | Incremental costs ($) | Incremental effectiveness (QALY) | ICER ($/QALY) |
| | Cochrane (base-case) | | | | | | | AZA | 54,249.98 | 1.6367 | | | | | MMF | 71,861.21 | 1.6434 | 17,611.23 | 0.0067 | 2,630,591.76 | |
Subgroups | | | | | | | ALMS | | | | | | | AZA | 55,959.12 | 1.6125 | | | | | MMF | 72,619.05 | 1.6363 | 16,659.92 | 0.0238 | 700,001.12 | | MAINTAIN | | | | | | | AZA | 54,527.62 | 1.6318 | | | | | MMF | 72,511.65 | 1.6148 | 17,984.04 | −0.0170 | Dominated |
|
|
| | Scenarios | ICER MMF versus AZA (US$) |
| | Base-case | 2,630,591.76 | | Excludes indirect costs in both strategies | 2,529,609.93 | | Utility | | | Remission = 0.8 (versus base-case 0.7) | 1,476,631.93 | | Relapse requiring MMF = 0.5 (versus base-case 0.6) | 1,654,369.09 | | Utility of relapse requiring CYC = utility of relapse requiring MMF rescue | 2,555,137.00 | | Conditions biased against AZA-based strategy | | | Indirect costs × 6 months during remission ($10,041.49) [higher indirect costs for AZA group] | 2,410,632.95 | | Indirect costs × 6 months during remission ($10,041.49) + utility of remission state (0.8) [higher indirect costs for AZA group + higher utility during remission] | 1,380,997.67 | | Indirect costs × 6 months during remission ($10,041.49) + utility of remission state (0.8) + drug costs of AZA × 6 months ($2626) [higher indirect costs for AZA group + higher utility during remission + higher drug costs of AZA] | 709,870.18 | | Revised assumptions | | | AZA group receives 3 gm/day of MMF as rescue (base-case 2 gm/day MMF) | 1,900,694.28 | | Patients in the AZA group who remit on CYC rescue therapy are treated with AZA maintenance therapy (base-case MMF 2 gm/day) | 2,273,422.51 |
|
|
